Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giovanni Di Perri

Showing results (11-20 of 438) with videos related to

Pageof 44
Sort By:
The New Microbiologica|October 3, 2022
Biofilm Development and Approaches to Biofilm Inhibition by ExopolysaccharidesGiovanni Di Perri, Guido Ferlazzo
Le Infezioni in Medicina|September 24, 2019
Drug-drug interactions in anti-HCV therapy: a comparison among options available in ItalyGiovanni Di Perri, Giuseppe Cariti
Le Infezioni in Medicina|September 11, 2025
Extending follow-up visits in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinionGiovanni Di Perri, Stefano Bonora
Le Infezioni in Medicina|June 17, 2026
The multifaceted antiretroviral coverage provided by BIC/FTC/TAF: a pharmacokinetic/pharmacodynamic revisitationGiovanni Di Perri, Andrea Calcagno
Annals of Internal Medicine|February 19, 2002
Quinine-induced blindness reversed by an increase in alpha1-acid glycoprotein levelGiovanni Di Perri, Benedetta Allegranzi, Stefano Bonora
Le Infezioni in Medicina|July 16, 2009
[HIV infection: treatment of naive patients]Stefano Bonora, Andrea Calcagno, Giovanni Di Perri
Clinical Pharmacokinetics|September 10, 2014
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous systemAndrea Calcagno, Giovanni Di Perri, Stefano Bonora
Pharmacogenomics|April 5, 2016
What do we know about tailoring treatment with tenofovir?Andrea Calcagno, Giovanni Di Perri, Stefano Bonora
The New England Journal of Medicine|August 31, 2012
Anti-CD20 antibody therapy for B-cell lymphomasAndrea Calcagno, Roberto Rostagno, Giovanni Di Perri
Hepatology (Baltimore, Md.)|July 28, 2006
Acute hepatitis C: dosage and complianceFrancesco De Rosa, Giuseppe Cariti, Giovanni Di Perri
Pageof 44

Showing results (11-20 of 438) with videos related to

Sort By:
Pageof 44
The New Microbiologica|October 3, 2022
Biofilm Development and Approaches to Biofilm Inhibition by ExopolysaccharidesGiovanni Di Perri, Guido Ferlazzo
Le Infezioni in Medicina|September 24, 2019
Drug-drug interactions in anti-HCV therapy: a comparison among options available in ItalyGiovanni Di Perri, Giuseppe Cariti
Le Infezioni in Medicina|September 11, 2025
Extending follow-up visits in people with HIV (PWH) receiving bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) therapy: an expert opinionGiovanni Di Perri, Stefano Bonora
Le Infezioni in Medicina|June 17, 2026
The multifaceted antiretroviral coverage provided by BIC/FTC/TAF: a pharmacokinetic/pharmacodynamic revisitationGiovanni Di Perri, Andrea Calcagno
Annals of Internal Medicine|February 19, 2002
Quinine-induced blindness reversed by an increase in alpha1-acid glycoprotein levelGiovanni Di Perri, Benedetta Allegranzi, Stefano Bonora
Le Infezioni in Medicina|July 16, 2009
[HIV infection: treatment of naive patients]Stefano Bonora, Andrea Calcagno, Giovanni Di Perri
Clinical Pharmacokinetics|September 10, 2014
Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous systemAndrea Calcagno, Giovanni Di Perri, Stefano Bonora
Pharmacogenomics|April 5, 2016
What do we know about tailoring treatment with tenofovir?Andrea Calcagno, Giovanni Di Perri, Stefano Bonora
The New England Journal of Medicine|August 31, 2012
Anti-CD20 antibody therapy for B-cell lymphomasAndrea Calcagno, Roberto Rostagno, Giovanni Di Perri
Hepatology (Baltimore, Md.)|July 28, 2006
Acute hepatitis C: dosage and complianceFrancesco De Rosa, Giuseppe Cariti, Giovanni Di Perri
Pageof 44